Hepatitis

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…

Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…

Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…

Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…

A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to sustained clearance of the…

A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would start treatment — and ultimately…

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…

Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of liver inflammation, can lead to…

The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of the awards going to scientist-led…

Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis B infections, and says data…